Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
Morana Vojnic(Memorial Sloan Kettering Cancer Center), Marc Ladanyi(Memorial Sloan Kettering Cancer Center), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), John T. Poirier(Memorial Sloan Kettering Cancer Center), Helena A. Yu(Memorial Sloan Kettering Cancer Center), Romel Somwar(Memorial Sloan Kettering Cancer Center), Andrew J. Plodkowski(Memorial Sloan Kettering Cancer Center), Mark G. Kris(Cornell University), Ken Suzawa(Okayama University), Charles M. Rudin(Memorial Sloan Kettering Cancer Center), Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Neal Rosen(Memorial Sloan Kettering Cancer Center), Christopher Kurzatkowski(Memorial Sloan Kettering Cancer Center), Ryma Benayed(Memorial Sloan Kettering Cancer Center), Daisuke Kubota(Memorial Sloan Kettering Cancer Center), Michael Offin(Memorial Sloan Kettering Cancer Center)
Cited by 97
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k